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1. Introduction 
In 2008 within the European Union brain cancer and cancer of the nervous system ranked 
number 15 within the 20 most diagnosed cancer types (Ferlay et al., 2010). Compared to the 
five most frequent cancer types brain cancer seems to have a small-sized incidence-rate, but 
the mortality rate for this type of cancer is much higher than those of most high-incidence-
cancers (except lung cancer). Though brain cancer is only seldom diagnosed, its negative 
impact on patients health status and well-being should not be disregarded, as survival 
prognosis is poor and deteriorated health-related quality of life (QOL) is common 
(Taphoorn et al., 2010). Treatment options comprise surgery, radiation, chemotherapy and 
supplementary medical therapies. Brain cancer is characterised by a large variety of tumour 
types and a distinction is made between primary tumours arising directly from brain tissue 
and secondary tumours, which are brain metastases from other malignant diseases. This 
differentiation is often difficult to make, though, it is of special importance since the best 
possible treatment e.g. for glioblastoma strongly differs from those for brain metastases 
(Campos et al., 2009) and inadequate intervention jeopardises patients’ QOL.  
Survival expectancy is strongly related to the WHO grade of the tumour and varies 
vigorously. Grade I tumours may not shorten life expectancy, grade II tumours are 
associated with a survival time of 2-10 years, grade III tumours with a survival time of 2-3 
years and grade IV tumours with a survival time of only 9-12 months (Reardon & Wen, 
2006). Not only the tumour itself, but also treatment-related side effects and adverse events 
caused by supportive medication (e.g. steroids and antiepileptic drugs (Sizoo et al., 2010)), 
confront the patient with a high level of physical and psychosocial burden. Brain tumour 
patients are affected by a diversity of tumour symptoms, which might be caused by 
increased intracranial pressure (e.g. headache, anorexia, seizures, nausea, vomiting, sleeping 
longer at night, drowsiness, napping during the day). Further physical impairments may 
occur due to focal neurological deficits (e.g. motor deficit, aphasia, visual field defects) and 
even more burdensome both for patients and care-givers might be symptoms like 
personality changes, decrease in mental capacity and concentration, mood disturbances, 
cognitive dysfunction, fatigue and anxiety (Heimans & Taphoorn, 2002; Sizoo et al., 2010). 
These symptoms were found to have a negative impact on both patients’ and their carers’ 
overall QOL if compared to general population (Janda et al., 2007). As brain tumour patients 
cannot be cured in most cases, the treatment has to focus on maintaining QOL, to make the 
patient's remaining life time as enjoyable as possible. 
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2. Patient-reported outcomes  
A short and concise definition of patient-reported outcomes (PROs) is presented by the Food 
and Drug Administration: "A PRO is a measurement of any aspect of a patient's health 
status that comes directly from the patient (i.e., without the interpretation of the patient's 
responses by a physician or anyone else)."(U.S. Food and drug administration (FDA), 2006). 
Therefore, PROs allow the comprehensive evaluation of patients’ perception of aspects of 
functioning and well-being in regard to their health status, disease, and its treatment. They 
comprise a variety of directly reported health-related issues: disease-related symptoms, 
treatment-related adverse events, functioning, well-being, health-related quality of life 
(QOL), perceptions about treatment, satisfaction with care and professional communication 
(Rothman et al., 2007). Commonly assessed PROs are e.g. QOL, depression, anxiety, pain, 
fatigue, gastrointestinal symptoms, social functioning, or perceived cognitive dysfunction. 
Thus, PROs are characterised by versatility in possible application, as they may be used for 
QOL evaluation both in clinical research and routine, for adverse event detection in drug-
safety reports and medical product development, and for guidance in medical decision 
making.  
Many studies already illustrate that PRO-data provides additional information, which is 
useful for medical decision-making and treatment choices. Two papers report the results 
from a study with newly diagnosed glioblastoma patients (Stupp et al., 2005; Taphoorn et 
al., 2005). Intensive treatment comprising radiotherapy and chemotherapy with 
temozolomide was compared to standard treatment in regard to survival and QOL. The 
combined treatment option was generally refused by clinicians, since they supposed the 
potential side-effects to outweigh the possible benefit of longer survival. PRO-assessment at 
baseline, during and after treatment showed that patients with combined radio- and 
temozolomide chemotherapy survived longer than patients with radiotherapy alone, 
without additional impairments of self-reported QOL. 
Marino et al. (2008) investigated QOL and overall survival in breast cancer patients 
receiving conventional chemotherapy or high-dose chemotherapy. PRO-data revealed that 
high-dose chemotherapy caused severe impairments in functioning scales and considerably 
high ailments due to nausea, fatigue and pain during active treatment. Furthermore 
patients’ QOL recovered more slowly when high-dose treatment was administered and 
QOL remained stable at a lower level than QOL of patients with standard treatment. This 
additional QOL impairment due to high-dose therapy was not associated with longer 
overall survival.  
A study conducted by Press et al. (2001) and Ganz et al. (2003) compared treatment options 
for patients with early Hodgkin’s disease. The patient group who received chemotherapy 
before standard treatment (subtotal lymphoid irradiation, SLI) did not suffer from higher 
toxicity, had a higher failure-free survival and fewer relapses or deaths than patients 
receiving only SLI. Though, these benefits in respect to clinical outcomes were associated to 
a greater severity of symptoms, more fatigue and poorer QOL six months after baseline. 
Nevertheless, it must be kept in mind that treatment with chemotherapy lasted twice as long 
as standard treatment and therefore time for recovery was longer in SLI patients. At the one 
year follow-up QOL-scores returned to baseline levels in both treatment groups.  
Individual patients as well as health care providers can benefit from PROs, as these may not 
only support patients in selecting an available treatment, but also enhance the general 
understanding of the disease and improve its treatment and the management of treatment-
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related side-effects. Additionally, PROs may alleviate the decisional hierarchy between 
clinicians and patients by involving both sides into the formulation of important health and 
QOL domains, which are considered to need clinical attention (Snyder et al., 2010). In this 
way, medical issues do not longer suppress QOL domains. Besides, by giving patients’ the 
possibility to contribute to the choice of medical treatment, their anxiety and depression can 
be reduced and their QOL improved (Arora, 2003). 
A high percentage of clinicians support the assessment of PRO-data, but only one third of 
them has knowledge about PRO-instruments and procedures for data collection (Bossola et 
al., 2010). This lack of understanding, of what PROs exactly are and what they can 
contribute in daily routine, could be one reason that clinicians see their authority questioned 
and refuse to work with PROs. However, PROs do not intent to compete with direct 
physician-patient communication or to replace clinicians’ expert opinion. PROs rather want 
to  improve the ability to identify and detect specific impairments and symptoms including 
psychological problems. The integration of patients’ individual perspective may also 
improve multi-professional cooperation and the combination of different medical and 
psychological treatment options to a patient-tailored and comprehensive therapeutic 
concept. Many clinicians argue that the use of PROs would take too much time, but it is 
reported that follow-up appointments did not or only 0.5 to 2.7 minutes prolong due to 
PRO-assessment (Frost et al., 2007).  
The additional value of PRO-data in clinical routine was shown in some randomised-
controlled trials. The prescription of pain medication in a mixed sample of cancer patients 
differed significantly between patients who completed a pain-self-rating and patients who 
did not. Prescriptions for patients who provided a self-report changed more often, both with 
increase and decrease. In patients without self-reports prescriptions changed less frequently 
and only with an increase (Trowbridge et al., 1997). In another study, clinical staff 
responsible for lung cancer patients was demonstrated how to read PRO-data and they were 
encouraged to use reports of these data to detect domains, which could guide the discussion 
about QOL with the patient. Patients whose clinicians used PRO-data reported more 
domains discussed in regard to QOL within the consultation (Taenzer et al., 2000). In 
patients with various cancer diagnoses undergoing palliative chemotherapy, the use of 
PRO-data before the follow-up visits prior to each chemotherapy cycle had a number of 
significant effects: communication about QOL issues improved, unobvious domains like 
social functioning and fatigue were more often discussed and patients’ felt to a larger extent 
emotionally supported. Clinicians showed a tendency to be more responsive to problems in 
unobvious QOL-domains. The duration of the follow-up visit was not prolonged by the use 
of PRO-data (Detmar et al., 2002a). Another population of cancer patients with different 
diagnoses receiving chemotherapy gave evidence that the explicit use of PRO-data can have 
a positive impact on patients’ QOL and emotional well-being (Velikova et al., 2004). Of these 
patients whose PRO-data was explicitly used, the vast majority rated the questionnaire to be 
useful to communicate personal feelings to the clinician (Velikova et al., 2010). 
Although studies have shown that PROs can be useful for enhancing communication in 
clinical routine, there are also studies that do not report a beneficial impact of PROs. Some 
studies did not find any effect of the usage of PRO-data on global QOL of patients (Drury et 
al., 2000; McLachlan et al., 2001; Detmar et al., 2002a). A randomized-controlled trial 
conducted by Rosenbloom et al. (2007) provided PRO-data and results of structured 
interviews of advanced cancer patients undergoing  chemotherapy to their nursing staff. No 
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effect of the mere provision of PRO-data on clinical management strategies, satisfaction or 
QOL was found. The authors suggest that the communication of PRO-data is only useful, if 
oncology staff is also provided with concrete information about treatment and care 
strategies for certain QOL-impairments. This criticism concerns all of the above mentioned 
studies investigating PROs in clinical routine, as none of them gives any specific treatment 
advice to clinicians (Taenzer et al., 2000; McLachlan et al., 2001; Detmar et al., 2002a; 
Velikova et al., 2004; Velikova et al., 2010).  
Osoba (2007) emphasizes that PROs can be useful at several stages of patient-management, 
especially when they are conducted in parallel to conventional medical procedures. Besides 
gathering information about patients’ medical history, physical exams, laboratory and 
imaging tests, treatment and follow-up, PROs may be used to support differential diagnosis 
and to monitor patients’ progress. Similar to these steps, which are associated with several 
courses of action, also PRO-data has to be associated with guidelines for clinicians, which 
interventions can be set, if impaired QOL-domains are detected. Clinicians have to be 
trained in PRO-data interpretation and in possibilities for QOL-focused support. By 
analogy, it would seem bizarre to argue that blood level analysis is useless, because 
clinicians do not adjust treatment in regard to these characteristic values due to insufficient 
knowledge about how to use them. Exactly this is a problem with PRO-data: most studies 
do not evaluate specific interventions imposed after PRO-data analysis, but only the 
collection of PROs. Some studies tell clinicians to use PRO-data within patient-clinician 
communication, but do not guide them how to use this data. Therefore the study results 
might depend on the open-mindedness, prior experience and the expertise about PRO-use 
of the clinician. Furthermore, some patients might already benefit from the mere collection 
of PRO-data and others might need focused intervention.  
Regarding the studies that did not find any positive effect of PRO-data, some further 
limitations have to be taken into account. There was only a low compliance of clinicians’ to 
pay attention to PRO-data and to use them regularly. Just a third of all possible offered 
interventions were used by patients and physical procedures were more often accepted than 
psychological consulting (McLachlan et al., 2001). Furthermore, ceiling effects may have 
disguised existing effects of PRO-data usage on patients’ satisfaction (Taenzer et al., 2000; 
Detmar et al., 2002a).  
Even if the results of randomized-controlled trials concerning the usage of PRO-data are 
mixed, there is evidence that PROs can enrich patient-clinician communication and in this 
way also influence patients’ QOL. PRO-completion seems not to impose an intolerable 
burden to patients and many studies report high acceptance of PROs – conducted as paper-
pencil or more sophisticated via a software program - even in sick patients (Mullen et al., 
2004; Bush et al., 2005). 
The acceptance of PROs by patients is usually very good, as they are capable to bridge the 
gap between favoured discussions on QOL-domains with their clinician and patients' 
hesitation to initiate these discussions themselves. Detmar et al. (2000) reported that QOL 
domains differ in regard to how often patients wish their clinician to start a conversation on 
a certain issue. Approximately 25-29% of patients wish their clinician to ask them about 
their emotional functioning, daily activities and familial issues. About 37% of patients 
expect their clinician to address the topic of social functioning. Hereby PROs can 
successfully contribute to satisfaction of clinicians and patients, as clinicians attain a deeper 
insight in patient’s needs and may properly address relevant topics and patients do not 
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need to answer a variety of possibly irrelevant questions during the face-to-face 
consultation. PROs may also sharpen clinicians’ awareness for psychological, social and 
spiritual functioning and diminish the domination of physical functioning in patient-doctor 
conversation (Rodriguez et al., 2010). 
2.1 PRO instruments 
For PRO-assessment in cancer patients, an extendable generic cancer core-questionnaire can 
be administered, which might be supplemented by disease-specific questionnaire-modules. 
Widely used, validated and reliable cancer-targeted instruments for instance are the 
European Organization for Research and Treatment of Cancer core questionnaire (EORTC 
QLQ-C30) and the Functional Assessment of Cancer Therapy general version (FACT-G). To 
both of these instruments a brain cancer-specific module can be added (QLQ-BN20 for the 
EORTC QLQ-C30 and FACT-Br and the FACT-Br Symptom Index (FBrSI) for the FACT-G). 
Table 1 gives an overview of the questionnaire characteristics.  
2.1.1 EORTC QLQ-C30 and QLQ-BN20 
The EORTC QLQ-C30 was originally developed to evaluate QOL in cancer patients 
participating in clinical trials (Aaronson et al., 1993) and is a nowadays widely used and 
internationally validated cancer-targeted PRO-instrument. The core questionnaire consists 
of thirty questions and is the basic part of the QOL-instrument, which can be expanded by 
additional elements. These supplementary modules focus on diagnosis-specific symptoms 
and impairments. Altogether, the QLQ-C30 comprises nine scales and six single item 
symptoms. Five scales concern various functioning domains (physical, role, social, 
emotional and cognitive functioning), one is a scale for global QOL, and three are symptom 
scales (pain, fatigue, nausea/vomiting). Except for the two questions about general QOL 
every question needs to be rated on a likert scale from “not at all”, “a little”, “quite a bit” to 
“very much”. The overall QOL scale asks the patients to grade how they experienced their 
general QOL and physical condition between 0 “very poor” and 6 “excellent”. With the 
exception of the physical functioning scale, all questions use a time frame of one week 
before the examination date.  
The EORTC Brain Cancer Module (QLQ-BN20) contains 20 items and focuses on symptoms 
that particularly concern brain cancer patients undergoing chemotherapy or radiotherapy. 
In this way, both disease symptoms and treatment toxicities are included in the item list 
(Sprangers et al., 1998). The QLQ-BN20 is divided into four scales (future uncertainty, visual 
disorder, communication deficit, motor dysfunction) and seven single items (headache, 
seizure, drowsiness, hair loss, itching, weakness of both legs, difficulty controlling bladder 
function) (Osoba et al., 2000). 
2.1.2 FACT-G and FACT-Br/FBrSI 
The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system 
provides questionnaires concerning a variety of chronic illnesses and their conditions, for 
instance cancer, HIV/AIDS, and multiple sclerosis. Within the FACIT the FACT-G 
questionnaire is a cancer-specific instrument for PRO-assessment (Webster et al., 2003). 
Nowadays the fourth version of the FACT-G is widely used and comprises 27 items 
grouped into four primary QOL domains (physical well-being, social/family well-being, 
emotional well-being, and functional well-being). The patient has to rate each item on a five-
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point Likert-scale between “not at all”, “a little bit”, “somewhat”, “quite a bit” and “very 
much” in relation to symptom severity during the last week. The FACT-G was examined 
concerning its ease of administration, brevity, reliability, validity and responsiveness to 
clinical change and was found to fit all the stipulated requirements (Cella et al., 1993). The 
questionnaire’s validity was also tested for a variety of language versions (Sanchez et al., 
2011). 
The brain cancer-specific FACT-Br module consists of 23 items and explores how patients 
perceive their cognitive, neurological, sensory and psychological functioning and the impact 
of changes in these domains on their daily living. Additionally, the FACT-Br Symptom 
Index (FBrSI) is available for symptom rating of brain tumour patients. Both the FACT-Br 
and FBrSI proved to be reliable, valid and responsive to change (Nickolov et al., 2005). 
instrument scales items 
FACT-G  
Functional Assessment 
of Cancer Therapy-
General  
- physical well-being  
- social/family well-being 
- emotional well-being 
- functional well-being 
27 
FACT-Br 
Functional Assessment 
of Cancer Therapy-Brain 
Module 
- cognitive functioning 
- neurological functioning 
- sensory functioning 
- psychological functioning 
- impact of changes in functioning on daily 
living. 
23 
FBrSI 
FACT-Br Symptom 
Index 
- brain tumour specific symptom list 15 
EORTC QLQ-C30 
European Organisation 
for Research and 
Treatment of Cancer 
Quality of Life 
Questionnaire Core 30  
- functioning (physical, role, social, emotional 
and cognitive)  
- global QOL 
- pain, fatigue, nausea/vomiting 
- dyspnoea, sleeping disturbances, appetite 
loss, constipation, diarrhoea and financial 
impact 
30 
EORTC QLQ-BN20 
European Organisation 
for Research and 
Treatment of Cancer 
Quality of Life Brain 
Module  
- future uncertainty 
- visual disorder 
- communication deficit 
- motor dysfunction) 
- headache, seizure, drowsiness, hair loss, 
itching, weakness of both legs, difficulty 
controlling bladder function 
20 
All instruments have been extensively validated. 
All instruments use a recall period of one week. 
Table 1.Commonly used PRO-instruments for cancer patients with brain modules available 
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2.2 The value of proxy-reported outcomes 
A common symptom burden in brain cancer patients are cognitive impairments, which may 
be caused by the disease itself or anti-cancer treatment. Although PROs are the method of 
choice for QOL-assessment, this method is not suitable for patients who suffer from 
deteriorated cognitive function. A large amount of patients is not able to complete PRO-
instruments due to serious malfunction in cognition, speech, vision, concentration or 
language. Even if these symptoms are perceived at a low level, PRO-assessment can be too 
burdensome for these patients and cause additional distress. This implies that the needs of a 
certain subgroup of patients are possibly not adequately met, because they are excluded 
from QOL-assessment and therefore also from intervention. Furthermore, the exclusion of 
these patients from longitudinal studies sugarcoat data and may produce compromising 
and misleading results (Sneeuw et al., 1997). Especially the subgroup of patients, who are 
not able to give information about their QOL themselves, might particularly be in need for 
intervention concerning impaired QOL-domains.  
A complementary source of information about patients’ QOL are therefore ratings from 
clinicians, nurses or significant others (spouses, children, family members or close friends). 
Normally, the usefulness of information provided by others on patients’ QOL is investigated 
by analysing the agreement of outsiders’ and patients’ ratings. Therefore, proxies or health 
care providers have to complete the same PRO-instrument as the patient. The degree of 
agreement or correlation of patients’ and others’ answers reflects the reliability of this 
approach for QOL-data collection. Generally, proxy ratings tend to overestimate patients’ 
symptom burden and underestimate their QOL, because proxies are in their ratings 
influenced by their own feelings and experiences of care-giving activities. Nevertheless, 
care-giving significant others are supposed to be a valuable source for information about 
patients’ QOL, especially for concrete and observable domains (Addington-Hall & Kalra, 
2001). In brain cancer patients there was exact agreement between proxies and patients 
found in 60% of the questions of the EORTC QLQ-C30 and the module BN20. If one 
category of difference in either direction was allowed, even over 90% of approximate 
agreement was obtained. There were only low correlations between ratings of social 
functioning, nausea/vomiting, and pain. Over time, agreement worsened significantly for 
patients whose condition deteriorated since the baseline assessment. Additionally, 
disagreements in answers were more likely if patients were more physically and 
neurologically impaired or mentally confused (Sneeuw et al., 1997).  
In brain cancer patients a moderate-to-high patient-proxy agreement for the Linear 
Analogue Self-Assessment (comprises questions concerning physical condition, social 
interactions, psychological effects of disease and personal relationships), for hope, confusion 
and sadness was reported (Hahn & Dunn, 2003). Brown et al. (2008) report for patients with 
newly diagnosed high-grade glioma a moderate-to-high patient-proxy agreement at the 
FACT-Br questionnaire. They also indicate that agreement was influenced by patients’ 
cognitive status. Low scores at the Folstein Mini-Mental State Examination were associated 
with a poorer agreement between proxies and patients in their rating of mood states. 
Giesinger et al. (2009a) report not only high discrepancies of patient-proxy rating for social 
functioning, dyspnoea and seizures, but also good agreement for the scales physical 
functioning, sleeping disturbances, appetite loss, constipation, financial impact and taste 
alterations (EORTC QLQ-C30 and BN20). They support the use of proxy-ratings for QOL-
assessment in brain cancer patients, but also critically note that general agreement is higher 
for physical symptoms than for psychosocial issues.  
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All in all, patients and proxies exactly agreed in their answers to a high extent and 
variations mostly did not exceed more than one answer category (Sneeuw et al., 1997). 
Cognitive impairments seem to worsen agreement between patients and proxies (Sneeuw et 
al., 1997; Brown et al., 2008). More obvious physical symptoms show better agreement rates 
than psychosocial issues (Giesinger et al., 2009b). Although proxy-patient agreement 
deteriorates over time if patient’s health and/or mental condition get worse, it still is 
reasonable to collect proxy-reported QOL-data for incorporating also the most ill patients in 
data-collection for intervention and research purposes. 
3. Electronic PRO-data capture 
Even though PRO assessments gain more and more importance in scientific research, e.g. 
concerning drug evaluation studies and label claim issues, they are not yet completely 
accepted as measurement method for adverse event detection, QOL-measurement and 
primary outcome in randomized controlled trials. Currently, many clinicians still consider 
clinician ratings’ as being sufficient for adequate evaluation of patients’ well-being and 
symptom burden (Basch, 2010). Patrick (2007) emphasizes the usefulness of PRO 
instruments, as they allow the capture of advantages and disadvantages of known or newly 
developed treatment options, which is valuable for choosing between therapies and for 
reasoning already chosen disease management strategies. One third of palliative cancer 
patients received adjusted treatment in respect to QOL improvement, but clinicians only 
focused on overall QOL instead of a variety of subscales and eclipsed QOL issues if patients 
showed tumour progression or increased treatment toxicity (Detmar et al., 2002b). This 
illustrates that specialized training for physicians is necessary to ladle the potential benefit 
of PRO-data in clinical routine. 
Walker et al. (2003) report administrative failure as most important reason for missing data 
(72.2 percent) in PRO-data collection in patients suffering from malignant glioma. About 
21.7 percent of patients did not fill out the PRO-instruments due to their very bad health 
condition and only 6.1 percent of patients refused to participate in PRO-assessments. The 
major problem of administrative failures in the study of Walker et al. (2003) can be traced to 
irregular administration time points of QOL PROs, too little explanation of instrument 
completion and missing specialized staff for QOL research who checks questionnaires for 
completeness. Such barriers can easily be overcome with the routine usage of electronic 
ePROs, which avoid a high percentage of missing data, as a standardized questionnaire 
explanation is integrated in the procedure and further questions are only displayed after all 
preceding questions have been answered.  
3.1 Requirements for ePRO and its implementation 
The implementation of ePRO in clinical routine requires some underlying circumstances, 
which enable effective QOL-evaluation. Firstly, there is a need for a comprehensive IT 
infrastructure that includes technical devices for data collection, software solutions for 
calculation and graphical illustration of results and network facilities for data-transmission, 
storage and backup. For data collection personal computers (PCs), laptops or personal 
digital assistants (PDAs) can be used. These devices differ in their feasibility according to 
patient-groups.  
For outpatients a fixed PC-workstation can be useful, since these patients are supposed to be 
in a relatively good health condition and able to see the PC by themselves. Portable devices 
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like laptops and PDAs seem to be more useful for inpatients, who are approached directly at 
the hospital bed. The IT infrastructure also should include a database for data storage and 
backup. A central database allows that clinicians from different wards have access to 
patients prior and latest QOL-assessments. A database connection can be established via a 
local area network (LAN) or Wifi (wireless fidelity, also WLAN, wireless local area 
network). Connection via LAN is more laborious as the study nurse needs to connect the 
tablet PC to the LAN with the purpose of preparing the patient list to who the questionnaire 
shall be administered. The tablet PC has to be disconnected, handed over to patients for bed-
side assessment and again connected to the LAN for uploading the collected information 
into the database.  
A connection provided by WiFi is much more comfortable, as the database can be updated 
anytime without special constraints. Wifi is nowadays a common and inexpensive 
technology that is also practicable in a hospital setting. Connection via WiFi eases work for 
both data collectors and clinicians, as data is transferred instantly and the immediate access 
to patients’ data is possible. Especially for home monitoring some additional requirements 
are added. If home monitoring is conducted via web-access, a feasible and user-friendly 
website with special security features is needed. Privacy of health information, data security 
and patients’ safety need special attention when developing an online PRO-platform (Basch 
et al., 2007). 
Secondly, clinicians and nurses need to be trained in two ways: on the one hand in device 
and software handling and on the other hand in choosing interventions according to PRO-
data. Acquaintance with technical equipment allows to answer most of patients’ questions 
and to solve minor problems directly on site. Training in result interpretation is also 
necessary, as PRO-data is supposed to give information about patients’ QOL and initiate 
thereby medical and/or psychosocial intervention. Although there are software solutions 
that offer easily interpretable graphs, precise instructions for interventions are still of crucial 
importance. Interpreting QOL-scores correctly is only the first step of successful ePRO-data 
use. The second step is to choose appropriate intervention strategies for QOL-management. 
Furthermore, a positive attitude of health care providers towards PRO-assessment is 
strongly necessary. Clinicians and nurses exert influence on patients and therefore also 
affect their compliance, since patients often orientate themselves by clinicians’ suggestions. 
The vivid contribution of clinicians and nurses to assess and use PRO-data may also carry 
patients along and support the whole PRO-procedure in all stages.  
3.2 Feasibility 
Velikova et al. (1999) report a high acceptance of ePRO in a mixed sample of cancer patients. 
Patients were asked to complete a paper-pencil as well as an electronic version of the 
EORTC QLQ-C30, with an interval of three hours between the two assessments. More than 
half of the patients preferred the ePRO version to the traditional paper-pencil questionnaire, 
whilst each 24% of patients preferred the paper-pencil questionnaire or had no preference. 
Overall, the ePRO version was slightly quicker completed by patients, whereas older 
patients in general needed more time to complete the PRO-instruments, independent of the 
type of administration. The quality of collected QOL-data was excellent if electronic 
assessment was used, as no missing data occurred. Although Velikova et al. (1999) 
hypothesized that patients would rather refuse to take part in a study, which demands them 
to use a computer for data-collection, compliance rates were similar to those in traditional 
therapeutic clinical trials.  
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The assessment of QOL by means of ePROs is also feasible in a clinical routine setting with a 
large number of mixed cancer patients attending the ward of an oncology clinic. Wright et 
al. (2003) conducted two feasibility studies, whose results underline that in comparison to a 
separate prospective patient sample (study 1), routine ePRO-assessment (study 2) reached 
higher compliance rates and therefore a better data-base for the description of changes over 
time. In both studies the majority of patients did not feel that the ePROs made their visit 
more difficult or temporally longer and only few patients said that they would refuse to 
complete ePROs as part of clinical routine. Most patients reported that the electronic 
equipment was easy to use and general feedback on ePROs was positive. 
Carlson et al. (2001) used a computerized version of the EORTC QLQ-C30 that was already 
successfully utilized by Taenzer et al. (2000) for investigating the ePRO-based changes in 
lung cancer outpatient care. Already in this previous study (Taenzer et al., 2000) the QOL-
tool was shown to be feasible and effective in sensitizing clinicians for QOL-issues. In the 
study of Carlson et al. (2001), the effectiveness of ePROs was examined with a group of 
patients with extensive symptom burden, who attended a cancer pain and symptom control 
clinic. The majority of patients rated the computerized EORTC QLQ-C30 version to be easy 
in use and well understandable. Their satisfaction with the ePRO was high and with 
repeated use of ePRO they judged the use of computers more favourably. Clinical staff felt 
that the ePRO was appropriate for QOL-assessment and useful for guiding the interaction 
with the patient. All in all, both highly impaired patients and health care providers support 
the use of ePRO and confirmed their feasibility and usefulness. 
3.3 Symptom monitoring and screening 
Brain cancer patients are affected by a variety of severe clinical symptoms. Since the survival 
time in most brain cancer patients is rigorously limited, early and symptom-focused 
intervention is of paramount importance. PRO-data works in two ways concerning 
symptom management. On the one hand, QOL-evaluation reveals impaired domains, which 
need targeted intervention. On the other hand, regularly assessed PRO-data allows 
achieving a deeper understanding of the impact of symptom management on a variety of 
symptoms besides the aimed symptom (Ganz & Goodwin, 2007). By way of example, there 
was the intention to improve physical functioning by pain reduction and PRO-data might 
show that other QOL-domains changed as well. PRO-assessments also capture unexpected 
developments and may illustrate interrelationships among QOL-domains (Ganz & 
Goodwin, 2007).  
Next to treatment-related symptoms, cancer patients have also to deal with psychosocial 
distress triggered by the disease itself and anti-cancer therapy. Since the inadequate or 
missing treatment of psychosocial distress may confront the patient with further 
impairments, as they might develop chronic mental disorders, early detection of 
psychosocial distress is necessary (Meraner et al., 2009). Effective screening for psychosocial 
distress can be performed by means of PRO-instruments like the Hospital Anxiety and 
Depression Scale (HADS) (Zigmond & Snaith, 1983) or the General Health Questionnaire 
(GHQ-12)  (Goldberg, 1972). Approximately 20-40 percent of cancer patients suffer from 
psychosocial distress and are therefore in need for referral to psychooncological treatment 
(Meraner et al., 2009). A study of Zabora et al. (2001) identified brain cancer patients to be 
highly endangered to perceive extensive psychosocial distress. Nearly 43 percent of brain 
cancer patients were tested positive with a distress screening by means of the Brief 
Symptom Inventory and ranked second after lung cancer with only tiny difference. For 
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these patients, PROs contribute in the detection of needs for psychooncological treatment 
and therefore prevent further ailments. 
As a screening tool is supposed to offer a quick possibility to check for impairments that 
require treatment, cut-off scores are of major importance. Additionally, the comparison to 
norm or reference values from general population or other cancer cohorts plays an essential 
role for the definition of impaired or normal QOL. For the interpretation of changes in PRO-
scores it is necessary to know, which score-deviations reflect clinical meaningful changes. 
Statistically significant effects are easily to find if a high number of patients contributed in 
PRO-data collection, but not every significant effect also must be a subjectively meaningful 
difference (Cella & Nowinski, 2002). To correctly interpret changes in PRO-scores, minimal 
important differences (MID) can be used. Jaeschke et al. (1989) described MID as the 
„smallest difference in score in the domain of interest which patients perceive as beneficial 
and which would mandate, in the absence of troublesome side effects and excessive cost, a 
change in patient’s management” (as cited in Dubois et al., 2006, p 977). MIDs are diverse 
for PRO-instruments and may also differ between diagnoses and disease stages (Revicki et 
al., 2008). Furthermore, they vary in dependence on how good baseline scores were and if 
QOL increased or deteriorated (Farivar et al., 2004). In addition, it is necessary to know if a 
change in the QOL-score is associated to the patients’ experience with a small, medium or 
large effect (Guyatt et al., 2002).  
There are considerable differences in the MIDs, depending on whether individual or group 
scores are used for analysis. For the EORTC QLQ-C30 and the FACIT system MIDs for 
group levels have been established but these MIDs should not be used in the same way for 
individual score interpretation (Giesinger et al., 2009a). On average unchanged QOL-scores 
of a group may also contain individual scores that meaningfully changed (Crosby et al., 
2003; Kemmler et al., 2010). Small changes on group level may be clinical significant, 
whereas on an individual level these changes do not reach clinical significance (Guyatt et al., 
2002), since small score differences in individuals may be due to measurement errors if they 
do not exceed the range of variation. Moreover, not every single patient experiences the 
average score change of the group, but a stronger or weaker score-deviation. Thus, group 
comparisons are used for the evaluation of various treatments and health policy decisions, 
while for actual clinical decision making conclusions derived from the individual level 
should be used (Crosby et al., 2003). These methodological considerations illustrate how 
important it is to train clinicians and nursing staff in PRO-data interpretation, since a correct 
understanding of the data is the basis for adequate intervention. 
3.4 ePRO software example 
For obtaining the highest grade of feasibility and utility of PRO-assessments, the use of 
specialized software that fits perfectly the needs of both patients and clinicians is obligatory. 
In recent years some effort has been undertaken to develop and implement software 
solutions for QOL-assessment in clinical routine, for instance by Joerg Sigle (AnyQuest) and 
Galina Velikova and Irma Verdonck (OncoQuest). These tools use touch screens and have 
shown to be feasible in clinical practice. Implementation studies suggest that routine 
patient-monitoring using a software solution for assessment is beneficial for clinicians, 
patients and medical care in general (Wright et al., 2003; Velikova et al., 2004; Rogausch et 
al., 2009).  
A further example for such a specific software solution is the computer-based health 
evaluation system (CHES). CHES has been especially been developed for electronic PRO-
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data capture and offers a variety of useful features for clinical routine and research 
purposes. Any required paper-pencil questionnaire can be implemented into the CHES 
program to facilitate all steps from data collection to result calculation, interpretation and 
statistical data analysis as well. CHES provides a database (e.g. MySQL or Oracle) for 
supplementary medical and psychosocial data. This database is particularly useful for 
research purposes, as it improves study logistics, reduces human resources and increases 
data quality. A so-called flag system enriches and facilitates the interpretation of QOL-data, 
since the implementation of reference values makes it possible to mark clinically relevant 
changes and problems. PRO-data can be accessed as a single assessment summary or as 
longitudinal graphical charts. The last one allows the immediate detection of changes and 
deficits in every single scale and gives an overview of the course of symptoms even if the 
clinician only takes a quick look at the graphs (Holzner et al., 2004). The availability of user-
friendly and well-tested software for PRO-assessments is the key for successful routine 
implementation of PROs. CHES already offers a variety of beneficial features for PRO-
application in clinical routine. A research project in cooperation with the EORCT Quality of 
Life Group (QLG) aims at the further development and distribution of CHES within the 
QLG for electronic QOL-assessment by means of the EORTC QLQ-C30 and its modules. The 
project comprises several steps of software development, multilingual software releases, a 
comprehensive manual and the work on additional features like computer-adaptive testing 
(CAT), telemonitoring and a web-forum for users and researchers.  
Holzner et al. (2011) implemented CHES for routine QOL monitoring at a neuro-oncological 
outpatient unit and reported it to be feasible, as routinely conducted ePRO-assessments 
could be easily integrated into the schedule of the ward. The integration of QOL-data 
profiles into interdisciplinary team meetings offered the benefit that possible problem 
domains can be detected at an early stage and patient-centred care can be improved. The use 
of CHES for PRO-collection was also well accepted by another population of brain tumour 
patients (Erharter et al., 2010). On average patients needed only ten minutes to complete the 
EORTC QLQ-30 and the QLQ-BN20. Furthermore, repeated instrument administration was 
associated with a decrease of the average completion time. Clinicians reported the ePRO to 
be beneficial, as e.g. loss of bladder controlling would not have been detected adequately 
without ePRO.  
3.4.1 Patient example for PRO-profile 
To give an example for patient-reported symptom trajectories Figure 1 shows the PRO-
profiles of the male patient D.K. born in 1953. He attended the hospital due to first 
occurence of epileptic seizures in December 2009 where diagnostic procedures revealed an 
astrocytoma (WHO grade III, right side, parietotemporal). After confirmation through 
stereotactic biopsy chemotherapy with temozolomide started in January 2010. In March 
2010, the patient was included in routine ePRO monitoring with EORTC QLQ-C30 and 
QLQ-BN20 at the neurooncological unit using the software CHES (see Figure 1).  
From April 2010 until May 2010 the patient received additional whole-brain radiotherapy. 
After end of therapy, the patient was seen monthly at the outpatient unit for follow-up. 
Figure 1 shows the course of self-reported physical functioning and motor dysfunction from 
March 2010 until October 2010. During this period, the initially high symptom level 
decreased considerably, reaching average scores. Horizontal lines in the charts in Figure 1 
show the 10th percentile (red), the 25th percentile (orange), and the 50th percentile (green) 
from a reference group of neurooncological outpatients. Colouring of bars corresponds to 
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these score ranges. Below each bar assessment date and abbreviation of treatment phase 
(chemotherapy (CT) and aftercare (AC)) is noted. Abbreviations on top of bars indicate 
specific interventions (pain intervention (PI) and psychooncological treatment (PO)). 
 
 
 
 
 
 
Fig. 1. Course of Physical Functioning (QLQ-C30) and Motor Dysfunction (QLQ-BN20) in a 
patient diagnosed with astrocytoma during chemotherapy and aftercare. 
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3.5 Home monitoring 
Even if QOL is regularly assessed within the hospital time schedule, information about 
patients’ well-being is still incomplete, as their PRO-monitoring ends with hospital 
discharge. ePRO makes it possible to follow patients’ in their home environment and to 
accompany them also during a phase, when hospital visits are not scheduled. Especially 
concerning chemotherapy, side-effects and treatment-related symptom burden are known to 
be most severe a few days after cytostatic drug application (Hawkins & Grunberg, 2009). At 
that time, patients mostly are already back at home and are therefore left alone with their 
management of occurring adverse events. Perceived symptoms during times spent at home 
may be underestimated due to missing patient-monitoring. This gap may be overcome by 
ePROs conducted via phone or web-based assessments (telemonitoring). Telemonitoring in 
combination with alert systems enable clinicians to contact patients suffering from severe 
symptom burden and intervene appropriately even when he/she is not hospitalized 
(Balducci & Stanta, 2000).  
PRO-data from assessments in clinical routine can be merged with data from home 
monitoring and provide a database, which potentially enable clinicians to get a deeper 
insight in disease and treatment-related symptoms in general and to identify signs of 
adverse events at an early stage. In this way, prospective intervention can be provided to 
minimize complications. However, comprehensive and close-meshed tele monotoring of 
patients’ QOL during their home stays requires additional administrative resources. 
Traditional paper-pencil questionnaires only have a low rate of return and are more 
expensive due to printing and postage costs. The internet provides an inexpensive and 
nowadays widespread technology that makes an easy, user friendly and reliable data 
collection possible. Though web-PROM imposes the need of a minimal computer literacy 
and internet use of patients, there is statistical data for Europe (Seybert & Lööf, 2010) that 
supports the assumption that web-PROM may be feasible in a considerable percentage of 
cancer patients. In 2010, 70% of European households had an internet connection and 69% of 
internet-users across all age groups used the internet regularly. The average rate of 
European internet-users who obtained health-related information via online sources 
doubled within the last six years (from 17% in 2004 to 34% in 2010) and is supposed to 
increase further. 
Although telemonitoring yet only reached an early stage of development, there are already a 
few studies available that document its use within oncological care. The most remarkable 
study was conducted by Bush et al. (2005) and collected QOL-data via web-PROM from 
patients who received hematopoietic stem cell transplantation. PRO-data was collected 
whether on a daily or monthly basis. Daily assessments consisted of only four out of 38 
items, which varied according to a quasi-random frequency, and a global QOL item. 
Monthly assessments included all 38 items at once and needed to be completed within two 
successive days. Patients had to visit a website and log in with a private user name and a 
password to enter the online QOL-assessment. Overall compliance for both daily and 
monthly assessments was good and only three patients discontinued study participation 
due to their bad health condition. Therefore, data show that this way of PRO-data collection 
does not only include the less sick patients. Furthermore, high feasibility of web-PROM, 
high patient acceptance and user satisfaction war reported. 
Telemonitoring takes patients’ QOL outside the hospital setting into account and contributes 
to its integration into symptom estimation, monitoring and treatment. Especially for brain 
cancer patients, telemonitoring could be of particular benefit, as it may increase their feeling 
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of security when they spend time at home. Eventually occurring symptoms are recognized 
by health care providers in real time despite the geographic distance between patient and 
medical services.  
3.6 Benefits from ePRO 
The traditional way of collecting PROs by means of paper-pencil questionnaires imposes 
several burdens to the patient, to clinical staff and financiers. Firstly missing data is more 
common in paper-pencil data collection as patients often may overlook an item and clinical 
staff is too busy to precisely control every single questionnaire. In addition, more human 
and time resources are needed, as questionnaires have to be printed in a sufficient number, 
tacked together, an stored so they can be handed over to patients, when needed. Subscales 
need to be calculated, put into an interpretable characteristic value and made accessible to 
clinicians. This procedure does not only gulp working time, costs for printing and staff, but 
is also vulnerable to missing data and errors in data transfer and calculation. ePRO-
assessment by means of electronic devices like laptops and tablet PCs prevent these error 
sources and save time as well as costs. Admittedly, ePROs need some seed money to acquire 
technical equipment and software, but with regular use these devices amortize soon as 
printing of multi-paged questionnaires is no longer necessary and staff costs are reduced.  
The implementation of PRO assessments of QOL or adverse events in clinical drug 
evaluation studies facilitates and accelerates data flow because intricate and defective data 
collection is cut short. Without PRO instruments clinicians ask patients about their 
symptoms and write a construed summary of these symptoms down in patients’ charts, 
from which research assistants collect information and consign them into research data 
bases (Trotti et al., 2007). This process is highly endangered to lose and/or alter information 
given by patients’ and needs much more human and time resources than the use of ePRO-
assessments. By means of touch screen equipped tablet PCs patients can easily complete the 
PRO-assessment themselves. The possibility to fit font and button sizes to the needs of 
different patients groups allows that readability and handling of the assessment is 
practicable for e.g. elderly people as well (Giesinger et al., 2009a). As no computer literacy of 
patients is needed for PRO-completion, in principle all patients are able to participate in 
ePROs. They were shown to be well accepted by patients (Mullen et al., 2004; Velikova et al., 
2010), valid (Abernethy et al., 2010) and equivalent to paper-pencil versions (Coons et al., 
2009). 
The advantage of time saving can also be applied to clinical routine. Admittedly, at the 
beginning of PRO implementation some time burden may be set on clinicians and nurses, as 
they need to be trained in software handling and result interpretation, but after a phase of 
familiarization PRO instruments contribute in time saving. Firstly, the completion of a PRO 
instrument encourages the patient to reflect more detailed on his/her health status and 
symptom burden and facilitates in that way the communication between patient and 
clinician/nurse about relevant problem areas. Secondly, via WiFi or LAN, patient’s ePRO-
data is immediately accessible for the clinician, whose attention can be called to clinically 
relevant deteriorations or improvements. In fact, such an alert system helps clinicians to 
focus on issues important for the patient without long-winded enquiry of possible 
difficulties. Queue times of patients might meaningfully be padded by PRO-completion.  
Furthermore, ePROs reduce staff costs, because score calculation, graphical illustration, alert 
systems and data storage are performed automatically. Time-saving aspects do not only 
concern data collection, but also identifying impaired QOL-domains. The implementation of 
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reference levels simplifies the comparison between patient-groups or patients and normal 
population and in this way the detection of problems in QOL. Automatically generated 
reports may comprise only affected scales, the complete assessment or trajectories over time, 
depending on which information the user is interested in. Due to the instantly performed 
data calculation, clinicians directly can be informed after PRO completion about clinically 
remarkable PRO data that need adequate intervention. Clinicians may therefore pick these 
notable domains and address them to the patient without the need to undertake a long-
winded exploration. In doing so, time can more effectively be spent on treatment and 
patient management, than on preliminary inquiry. The illustration of results by means of 
eye-catching and meaningful coloured graphs makes interpretation comfortable for both 
clinician and patient. Software solutions that include a storage database also simplify long-
term data storage and backup. ePROs enhance data quality, since missing data is prevented 
by forwarding only to the remaining questions when all prior items were answered.  
One common criticism to PROs is that patients are forced to answer annoying questions, 
which might be irrelevant to them. The development of CAT eradicates this flaw and makes 
ePRO-assessments for patients even more comfortable. CAT generates a patient-tailored 
question set and chooses appropriate items based on preceding answers. Information about 
diagnosis, progress of disease and treatment can also be considered for question compilation 
(Snyder et al., 2010).  
Although many advantages of PRO assessments can be communicated, there are still 
popular counter-arguments rampant. Even if PRO-data is available many clinicians do not 
pay attention to them because of lack of time, human resources and an adequate PRO-
instrument and the assumption that directly from patients obtained information does not 
add any additional value (Luckett et al., 2009). Furthermore some clinicians argue that 
information on QOL are not of same importance as treatment decisions (Morris et al., 1998), 
equality of PRO instruments is doubtful (Barlesi et al., 2006) and the methodology of PRO 
measurement seems to be dubious. These objections can be devitalised, though. Meanwhile 
a broad variety of internationally validated and widely used PRO instruments is available 
(especially for cancer populations the forgoing mentioned EORTC QLQ-C30 and the FACT-
G with their supplemental modules). The use of PRO-instruments does usually not or only a 
few minutes prolong the clinical appointment (Frost et al., 2007). Particularly the 
implementation of ePROs solves the problem of time constraints as data is directly entered 
by patients, scores are calculated automatically and immediate information processing is 
possible. Electronic data capture was shown to need less time for instrument completion 
than paper-pencil versions (Drummond et al., 1995; Velikova et al., 1999; Taenzer et al., 
2000). Table 2 summarizes pros and cons of PRO-assessments and illustrates, which benefits 
might outweigh commonly cited disadvantages of PRO-assessments. 
Some studies illustrate that in clinical routine the usage of PROs offers further benefits than 
only time and cost saving. Based on PRO-data clinicians adjusted the dosage of analgesics in 
a more sophisticated way than without PRO-data (Trowbridge et al., 1997). The patient-
clinician communication was improved (Taenzer et al., 2000; Detmar et al., 2002a) and 
enhanced concerning discussed domains (Detmar et al., 2002a), if clinicians took advantage 
of provided QOL-data. Furthermore patients felt higher emotional support, clinicians 
became more sensitive for normally underestimated QOL-domains (Detmar et al., 2002a), 
patients were more satisfied with care and the building of a relationship to the clinician 
(Velikova et al., 2010) and reported a better QOL (Velikova et al., 2004).  
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advantages of PROs disadvantages of PROs 
direct assessment of patients’ perspective 
without intermediary (e.g. clinicians, proxies)
additional burden for patients 
individually tailored therapy approaches in 
regard to PRO-data, targeted intervention 
(medical, psychological) 
improvement of patient-clinician 
communication 
detection of unobvious problem domains (e.g. 
social domains, fatigue, sexual issues) 
heightened awareness of clinicians for 
unobvious problem areas 
patients‘ support in clinical decision making
longitudinal PRO-data capture allows to track 
the impact of medical intervention 
ePRO: provide automated results calculation 
and graphical presentation 
additional resources necessary (time, human 
and financial resources) 
time-saving assessment of relevant problem 
domains that need special attention 
large variety of validated PRO-instruments 
(generic and specified) 
dubious comparability of PRO-instruments 
CAT (computer adaptive testing) makes it 
possible to fit PROs to the patients’ needs 
current, static PRO-instruments include also 
items irrelevant to a patients’ current health 
status 
Table 2. Advantages and disadvantages of PRO-assessments 
4. Conclusion 
The raising recognition of the patients’ perspective in clinical research, drug evaluation and 
label claim issues demonstrate the importance of PRO-assessments. However, PROs could 
be used in more clinical settings than they are now implemented. Especially in clinical 
www.intechopen.com
 
Diagnostic Techniques and Surgical Management of Brain Tumors 
 
20
routine PRO-data have a variety of benefits to offer, since already their mere administration 
potentially has positive effects on patients and clinicians.  
Recapitulating, the practical implications of this chapter are the following: The use of PROs 
within clinical routine is easily realizable since validated and reliable instruments are 
available. The conduction of PRO-assessments is further facilitated by effortlessly 
manageable software solutions. The participation in PROs encourages the patient to reflect 
detailed on different domains of their QOL even before the appointment with the clinician. 
Immediately transferred PRO-data enables the clinician to purposefully guide the 
conversation towards issues the patients reported to be important. In this way, time 
resources are optimal utilized: Queuing time is reasonably spent, because the patient gets 
prepared for the visit and within the appointment the clinician can spend more time on 
intervention and treatment. PROs allow therefore a targeted patient-clinician 
communication and a comprehensive as well as systematically performed screening for 
symptoms and impairments. 
Concerning the feasibility of PRO-assessments within the schedule of a busy oncology clinic, 
ePROs and constantly ongoing software development support the regular use of these 
measures also with neurooncological patients. It is of crucial importance to fit available 
PRO-instruments and their electronic administration to the needs of health care providers’ 
daily procedures. The smooth and effective implementation of PROs in clinical routine 
makes it more likely that they are accepted and supported by clinicians and nurses. 
Although the acceptance of PROs by patients is of major importance, the health care 
providers’ attitude towards QOL-measurement should not be disregarded. Clinicians’ 
contribution to PRO-assessment and PRO-data use influences substantially the success and 
effectiveness of PROs. The way how clinicians introduce PROs to patients may influence 
their feelings about them as well as their willingness to contribute. If patients are 
approached with a positive attitude they might experience PROs as an additional benefit 
instead of a further burden. Therefore, health care providers need to be directly approached 
to actively participate in QOL-measurement in the neurooncological setting. Even if patients 
are no longer able to provide self-reports, as it might especially occur in neurooncological 
patients, it is useful to ask significant others to substitutionally rate patients’ QOL to 
continue the assessment of the patients’ perception for symptom management. 
Especially in neurooncological patients, whose median survival expectancy is rather low, it 
is of particular importance to assess QOL in order to be able to quickly intervene if 
impairments occur. The routine use of PRO-instruments allows a constant patient 
monitoring with little effort, which nevertheless makes individualized treatment possible. 
That patient-centred care is highly needed is demonstrated by study results of Bosma et al. 
(2009). They report that glioma patients differ in their QOL-patterns in regard to their 
survival time. Patients with a shorter survival (death within one year from diagnosis) were 
reported to have more general health problems during the course of disease and an increase 
of weakness of legs until four months after baseline. On the other hand, long-term survivors 
(still alive two years after diagnosis) had fewer general health problems, showed 
improvements of physical, social and emotional functioning and had stable or even 
decreasing brain specific symptom levels.  The limited survival of most brain cancer patients 
requires a special focus on QOL, since curative treatment is unlikely and other aspects of life 
become more important. 
Methodologically, there is still the need to establish reference scores for brain cancer patients 
with different diagnoses undergoing diverse therapies. Furthermore, there is a lack of 
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randomized-controlled trials that investigate the effect of ePRO-based, targeted 
interventions in clinical routine. Future studies should put a focus on the evaluation of the 
precise impact of ePROs on medical care. A comprehensive knowledge about the impact of 
ePROs on the patient-clinician communication and on the provision of medical and 
psychosocial interventions would facilitate the patient-centred care and could therefore 
contribute to QOL improvement. 
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